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ABSTRACT
Introduction: Thalassaemia is an inherited blood disorder and is a significant public health alarm in Malaysia 
with many not knowing they are carriers of this haemoglobin disorders.  Materials and methods: This study 
conducted a one off collection of blood samples from 72 Malays students of International Islamic University 
Malaysia (IIUM) in Kuantan.  Blood samples were subjected to conventional haemoglobin analyses that include 
full blood count and picture, HPLC, Haemoglobin electrophoresis and H-inclusion test. All samples were also 
genotyped for alpha thalassaemia–1 of Southeast Asia (a-Thal1SEA).  Result: There were 17(23.6%) students 
who were diagnosed as thalassaemia carriers.  Out of this, four (5.5 %) and six (8.3 %) students were pre-
sumptive β-thalassaemia trait and Haemoglobin-E trait as determined by the HPLC assay respectively.  Nine 
(12.5%) students were genotyped a-Thal1SEA among whom two were also β-thalassaemia carriers.  All thal-
assaemia cases had MCH of < 27pg.  Nonetheless, two out of six Haemoglobin-E trait and three out of nine 
a-Thal1SEA carrier had MCV value of >80fL. Two out of four (50%) presumptive β -thalassaemia trait and one 
out of six (17%) students of presumptive Haemoglobin-E trait had family history of thalassaemia respectively. 
Conclusion: The high occurrence of the three common types of thalassaemia carrier (β, Hb-E and a-Thal1SEA 
thalassaemia) in our small group of subjects could be due to better participation of students who had family 
history of thalassaemia.  The study reaffirmed the importance of molecular study for detection of alpha-thal-
assaemia and the use of MCH value of <27pg rather than MCV value of < 80fL for prediction of thalassaemia.
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INTRODUCTION
Thalassaemia is a group of inherited autosomal re-
cessive blood disorders characterized by impaired or 
the absence of production of normal α or β globin 
chain peptide.  These groups of single gene disorders 
have an estimated 5% prevalence as carriers.1 In Ma-
laysia the prevalence is estimated to range between 
3% and 50% for Haemoglobin-E (Hb-E), 3% and 16% for 
α- thalassaemia and slightly lower for β-thalassaemia 
and Constant Spring carriers of 3% and 4% and 1% and 
4% respectively.2 The estimated prevalence for Hb-E 
and alpha thalassaemia in Malaysia is similar to the 
reported prevalence in Thailand, a neighboring coun-
try.3 
Symptomatic thalassaemia major and intermedia re-
quires life long-term medical care and support.4 Popu-
lation screening for carrier detection has been advo-
cated to reduce it occurrence and is being practiced 
in many countries.5,6 The best mechanism to do this, 
however, is still debatable since this would require 
huge financial resources to cover various areas such 
as the counseling service and genetic support.  In Ma-
laysia, most community health centers are equipped 
with blood cell analyzer, and it is therefore feasible 
to adopt the screening method based on the MCV of 
<80fL or MCH of <27 pg.  
In this study, a complete work-up for thalassaemia 
which include conventional methods for haemoglobin 
analyses and molecular study for a-Thal1SEA dele-
tion were performed in our group of students who 
responded to our advertisement for thalassaemia 
screening.  To mimic on site population screening, a 
one off blood collection was done.  
MATERIALS AND METHODS 
Subjects and blood analyses
The entire study was carried out over a period of 
three months following approval from the ethics and 
research committees of International Islamic Univer-
sity of Malaysia (IIUM).   Study subjects were medical 
and science students of the IIUM, who were recruited 
by announcement on notice boards.  To mimic a pop-
ulation-screening programme, blood sample from all 
72 Malay students aged 20-25 years was collected on 
the same day. 
The handling and storage of blood samples were in 
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assay on D-10 HPLC Haemoglobin Testing System (Bio-
Rad, USA) was performed within two days of the col-
lection of the blood samples.  The full blood count 
was performed within 24 hours after the blood col-
lection.  Other standard tests performed were the 
haemoglobin electrophoresis and H inclusion test. 
The full blood count was performed on automated 
ADVIA® 120-Haematology System. The haemoglobin 
electrophoresis was run on Hydrasys (Serbia, USA). 
H-inclusion test was performed by a junior laboratory 
technologist.
The chromatographic profiles and the HbA2 and Hb F 
levels determined by HPLC assays were interpreted 
based on the study by Fucharoen et al.7 Thus, a pre-
sumptive β-thalassaemia trait was made when HbA2 
level was from 4.2 to 6.8% while presumptive Hb-E 
trait and Hb-E homozygous were made when the HbA2 
was from 25% to 36% and 85% to 95% respectively. All 
samples were subjected to a-Thal1SEA molecular 
study regardless of the HPLC finding. Results were 
analysed using the Statistical Package for Social Sci-
ences version 11 (SPSS Inc., Chicago, Illinois, USA). A 
p value of < 0.05 was considered as statistically sig-
nificant.
Molecular analysis of a-Thal1SEA thalassaemia.
DNA was extracted by standard method using column 
separation method (QiaAmp Blood Mini Kit, Qiagen). 
The three primers for a-Thal1SEA genotyping were as 
described by Chang et al.8 The Gap Polymerase Chain 
Reaction assay consisted of 200 µm of each dNTP, 2.5 
mM MgCl2, 1X Q solution (Qiagen, Hilda, Germany), 
2.5 U HotStar Taq DNA polymerase, 100-200 ng of ge-
nomic DNA and distilled water made to 50 µL of cycle 
reaction. Reactions were run in thermal cycler (9700 
Gene Amp, Applied Biosystem, USA). An initial 10 min-
utes denaturation at 96ºC was followed by 35 cycles 
of 96ºC denaturation, 60ºC annealing and 72ºC exten-
sion, each for 30 seconds. A final extension at 72ºC for 
10 minutes ended up the reaction. All amplified prod-
ucts were run on 1.5% agarose gel electrophoresis and 
viewed on gel documentation system. The expected 
product for heterozygous a-Thal1SEA deletion is 314 
and 195 bp whilst the homozygous a-Thal1SEA dele-
tion is 195bp. The expected product for a-Thal1SEA 
negative amplicon is 314bp. The DNA of a known a-
Thal1SEA thalassaemia patient was used as the posi-
tive control. Positive samples were repeated at least 
once.  
RESULTS 
Of the 72 Malay students who responded for thalas-
saemia screening, the majority was females (87.5%). 
The haemoglobin (Hb) levels of all the students were 
normally distributed with the mean Hb of 13.9 g/dL in 
males; and 12.3 g/dL in females.  Ten students (13.9%) 
had low Hb level of whom only one was a male stu-
dent (cut off Hb< 11.5 g/dL for female and < 12.5 g/
dL for male). 
There were four (5.5%) students with a presump-
tive  β-thalassaemia trait and six (8.3%) with Hb-E 
trait.   Two out of four students with the presump-
tive  β-thalassaemia trait was a twin who had strong 
family history of clinical thalassaemia.   The mo-
lecular analysis detected nine (12.5%) students with 
a-Thal1SEA genotype (Figure 1), two of whom were 
also β-thalassaemia carriers detected earlier through 
HPLC assay.  None had a positive H inclusion test.   In 
total of 17 (23.6%) students were diagnosed as thal-
assaemia carriers (presumptive or through molecular 
study).  
Table 1:   Data on MCV values and types of  
thalassaemia
*Fisher-exact test
Figure 1: Gap PCR for --sea/αα thalassaemia. Lane 
1; 100bp marker , Lane 2,3 : Negative (315bp), Lane 
4,5, Positive (194 & 315bp), Lane 6: Blank  and  Lane 
7: Control negative (315bp)
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Out of 72 samples studied, 19 (26.38%) subjects had 
both low MCV and MCH value.  All subjects diagnosed 
as thalassaemia carrier had MCH of < 27pg thus further 
statistical analyses on this parameter were deemed 
unnecessary.  All the presumptive β-thalassaemia trait 
subjects had MCV levels of <75 fL.  There was a signifi-
cant association between the MCV level of <80 fL with 
a-Thal1SEA thalassaemia (two tails Fisher’s Exact test, 
p=0.008) and MCV level of <80 fL with Haemoglobin-E 
trait (Fisher exact test, p=0.038) (Table 1).  Neverthe-
less, the MCV value was normal (>80 fL) in two out of 
six subjects with presumptive diagnosis of Hb-E trait 
and three out of nine subjects with a-Thal1SEA. The 
median of Hb irrespective of sex for β-thalassaemia 
carriers was 9.8 g/dL, while the mean for Hb-E traits 
and a-Thal1SEA carriers were 13.3 g/dL and 11.5 g/
dL respectively.  The median Hb for subjects with con-
comitant evidence of β-thalassaemia and a-Thal1SEA 
was normal at 12.5 g/dL. There were two subjects 
with hypochromic microcytic anemia but with normal 
haemoglobin analysis findings.  No further investiga-
tion was done to determine another possible cause/s 
of anemia. 
Counseling was done for students with presumptive 
β-thalassaemia carriers and Hb-E carriers but none of 
α-thalassaemia carrier since the result was only avail-
able after the students left the university.  Two out 
of four students of presumptive β-thalassaemia car-
riers and one out of six students of Hb-E carriers had 
family members with thalassaemia.  Family history of 
thalassaemia could not be determined in all the cases 
of SEA thalassaemia carriers except in one who was 
also positive for β-thalassaemia carriers and had fam-
ily history of thalassaemia.
DISCUSSION
The standard protocol for screening of thalassaemia 
normally follows a defined flowchart wherein the 
erythrocyte indices are taken as the preliminary test. 
Generally only those with MCV level of <80 fL and/or 
MCH level of <27 pg are further tested using HPLC and 
molecular analyses.  In Malaysia, MCH level of < 27pg 
is adopted as the cut-off value.  The MCV level was 
of special interest in our study subjects since blood 
samples were collected and analysed within 24 hours 
of collection and has been the preferred indices in 
other screening centres.9  
Even though the MCV value of < 80fL was used for 
definition of microcytic red blood cells, all the pre-
sumptive β-thalassaemia trait subjects in our study 
had MCV level of <75 fL, which was similar to previous 
observations.10 Mah et al11 however, found that using 
a cut of value of <75 fL had led to missing detection 
of almost 3% of β-thalassaemia carriers and 4% of a-
Thal1SEA carrier subjects in the Chinese population, 
while the use of standard cut-off value of 80 fL could 
detect both carrier states.  The second observation 
was not replicated in our study as three out of nine 
(33.3%) of a-Thal1SEA genotyped subjects had MCV of 
> 80 fL.  Our data agrees with the findings of previ-
ous studies that concluded a proportion of Hb-E and 
α-thalassaemia carrier individuals would be missed if 
the MCV <80 fL cut-off value was used.11,12 Using the 
MCH value is most probably the preferred choice be-
cause in practice it might be difficult to analyze MCV 
values within six hours of collection. This is especially 
true if the collection centres are at the remote areas. 
In our study, we found all the thalassaemia carrier 
subjects had MCH value of less than <27 pg. This ap-
proach, however, is not without deficiency as some 
Hb-E trait and α-thalassaemia subjects in a larger 
study  were shown to have higher MCH value.13 All of 
our HbE trait subjects (n=6) had low MCH whilst two 
subjects had MCV>80fL.  Thus, MCH rather than MCV 
was the preferred parameter for screening of thal-
assaemia. Using the preset cut-off MCV value alone is 
confounded with missed detection of Hb-E trait.  
The use of H-inclusion test for screening of 
α-thalassaemia is an observer dependent, laborious 
and has a poor sensitivity.  Even though the staining 
procedures were carried out by following the stan-
dard H-inclusion protocol, fresh sample of control 
positive blood was not available on the day of this 
examination.  This could contribute to the failure in 
identifying any positive H-inclusion in all subjects 
with a-Thal1SEA genotype.  We believe the observer 
lacked of experience in interpreting H-inclusion test 
had also contributed to this failure.
The finding of this study does not reflect the preva-
lence of thalassaemia among Malays in Malaysia since 
the sample size was very small.  However, it was ob-
served that the distribution of Hb-E carriers among 
our Malay students were within the range of the pre-
vious review on thalassaemia in the general popula-
tion, and not very different either to a recent study 
done in Thailand.14 There were over representation 
of a-Thal1SEA and β-thalassaemia carrier subjects as 
compared to previous studies.15,16 It should be noted, 
however, that data from our study was very similar 
to the prevalence observed amongst Malays in Singa-
pore,17 a southern neighbouring country that has simi-
lar multiracial communities.  The percentage of Hb-E 
and β-thalassaemia carriers were also quite similar to 
the data done on blood donors.18 The study, however, 
did not examine for a-Thal1SEA genotype.  As this 
purpose of study was not to determine the prevalence 
of thalassaemia in general community, the high occur-
rence of thalassaemia in our subjects could be due to 
significant participation from students who had a fam-
ily history of thalassaemia.   The over-representation 
of subjects with a-Thal1SEA genotype could also be 
due to the contribution from subjects of mixed ethnic 
groups but were identified as Malay in this study. 
CONCLUSION
This study reaffirms the importance of molecular study 
for detection of alpha-thalassaemia carrier.  The MCH 
value of < 27pg is the preferred parameter for predic-
tion of thalassaemia carrier as the use of MCV of < 
80fL has led to miss detection of some Haemoglobin-E 
and a-Thal1SEA carrier.  Thalassaemia is prevalent in 
Malays; this study supports the opinion that popula-
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